It has been also demonstrated that BST-1/CD157 is involved in the progression and differentiation of leukemia (23–25), metastasis of ovarian carcinoma cells (26–28), malignant mesothelioma (29, 30) and glioma (31), and thus could be used as diagnostic or prognostic markers. This evidence concerns the gene BST1 and glioma.